The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations

PIK3CA, one of the two most frequently mutated oncogenes in human tumors, codes for p110α, the catalytic subunit of a phosphatidylinositol 3-kinase, isoform α (PI3Kα, p110α/p85). Here, we report a 3.0 angstrom resolution structure of a complex between p110α and a polypeptide containing the p110α-binding domains of p85α, a protein required for its enzymatic activity. The structure shows that many of the mutations occur at residues lying at the interfaces between p110α and p85α or between the kinase domain of p110α and other domains within the catalytic subunit. Disruptions of these interactions are likely to affect the regulation of kinase activity by p85 or the catalytic activity of the enzyme, respectively. In addition to providing new insights about the structure of PI3Kα, these results suggest specific mechanisms for the effect of oncogenic mutations in p110α and p85α.

[1]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[2]  P. Vogt,et al.  Cancer-specific mutations in phosphatidylinositol 3-kinase. , 2007, Trends in biochemical sciences.

[3]  K. Shokat,et al.  Chemically targeting the PI3K family. , 2007, Biochemical Society transactions.

[4]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[5]  P. Vogt,et al.  Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[7]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[8]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[9]  M. Girvin,et al.  Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit* , 2005, Journal of Biological Chemistry.

[10]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[11]  T. Kawabe,et al.  Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.

[12]  A. Lash,et al.  Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.

[13]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[14]  Y. J. Kim,et al.  Genetic polymorphisms in the transforming growth factor beta‐induced gene associated with BMI , 2005, Human mutation.

[15]  Suk Woo Nam,et al.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.

[16]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[18]  R. McLendon,et al.  Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.

[19]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[21]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[22]  G. Reifenberger,et al.  Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl‐lnositol‐3′‐Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas , 2003, Brain pathology.

[23]  M. Wolter,et al.  Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components , 2002, Genes, chromosomes & cancer.

[24]  J. Blenis,et al.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.

[25]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[26]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[27]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[28]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[29]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Stefanie Dimmeler,et al.  Akt-Dependent Phosphorylation of p21Cip1 Regulates PCNA Binding and Proliferation of Endothelial Cells , 2001, Molecular and Cellular Biology.

[31]  Roger L. Williams,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[32]  M. Lawlor,et al.  Insulin-Like Growth Factor-Mediated Muscle Cell Survival: Central Roles for Akt and Cyclin-Dependent Kinase Inhibitor p21 , 2000, Molecular and Cellular Biology.

[33]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[34]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[35]  D. Alessi,et al.  Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. , 1999, The Biochemical journal.

[36]  M. Waterfield,et al.  Signaling by distinct classes of phosphoinositide 3-kinases. , 1999, Experimental cell research.

[37]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[38]  J. Romashkova,et al.  NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.

[39]  P. Cohen,et al.  Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B* , 1999, The Journal of Biological Chemistry.

[40]  P. Cohen,et al.  Phosphorylation of Serine 256 by Protein Kinase B Disrupts Transactivation by FKHR and Mediates Effects of Insulin on Insulin-like Growth Factor-binding Protein-1 Promoter Activity through a Conserved Insulin Response Sequence* , 1999, The Journal of Biological Chemistry.

[41]  J. Dixon,et al.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.

[42]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[43]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[44]  J. Backer,et al.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. , 1998, The Journal of biological chemistry.

[45]  J. Downward,et al.  Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3‐kinase , 1998, The EMBO journal.

[46]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[47]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[48]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[49]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[50]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[51]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Harrison,et al.  Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes , 1996, Nature Structural Biology.

[53]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[54]  M. Kasuga,et al.  A biosensor approach to probe the structure and function of the p85 alpha subunit of the phosphatidylinositol 3-kinase complex. , 1993, The Journal of biological chemistry.

[55]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[57]  John F. Timms,et al.  Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer , 2001 .

[58]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.